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To Friends of the Department of Medicine
It has been a historic year for the Nation, City of Philadelphia and the
Jefferson Internal Medicine Residency Program. We have experienced
many health care crises starting with the closure of the historic Philadelphia
hospital, Hahnemann. We welcomed residents from this program as part
of the Jefferson Family and integrated many patients into our practices.
This was followed by the first pandemic in over a century. Through all of
this as the Program Director, I have never been prouder of our residents.
They have risen to every challenge with grace and poise working
alongside faculty to support the Jefferson mission: We Improve Lives.
This mission has never been more important as people across the country
protest the institutional racism that plagues this country. In the midst of
all of this the residents have still completed research, quality improvement
projects and contributed to the humanities. This publication is just one
example of the passion, dedication and creativity our residents continue
to provide to the Jefferson Community.
This journal, now in its 21th edition, continues to exemplify the perseverance,
inquisitiveness and talent of our Internal Medicine residents. Congratulations
to the Editors and all of the residents who contributed to another amazing
edition of the Forum. I hope you will enjoy reading it!
Emily Stewart, MD, FACP
Associate Professor of Medicine
Program Director Internal Medicine Residency
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We are delighted to present you with the 21st annual edition of The Medicine Forum.
Here in the birthplace of our nation, we like to think of The Medicine Forum as being
of the housestaff, by the housestaff and for the housestaff. Undeniably, this publication
would not be possible without the countless hours dedicated by our residents,
students, fellows and faculty.
This year has not been normal. The international healthcare community has been
confronted by a pandemic that has posed challenges unlike anything seen by our
generation. Our residents and faculty have been at the frontline of treating and better
understanding Covid-19. While we eagerly await the results of multiple clinical trials
that will continue to shape our management of this disease, we are also excited to
share other areas of ongoing scholarship within our department.
As always, thank you for reading The Medicine Forum. We hope you will continue
to support us in the years to come.
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CLINICAL IMAGES

Bilateral Intercostal Lung Herniations:
A Rare Incidental Finding in a Dyspneic Patient
Jillian Cooper, MD and Christine Kurian, MD

CASE PRESENTATION
A 63-year-old man with a past medical history of chronic
obstructive pulmonary disease (COPD), stage IV sarcoidosis
on 3-4 liters of home oxygen and chronic prednisone,
moderate aortic stenosis, and a prior aspergilloma for
which he had a left upper lobe lung resection presented
to the hospital with two weeks of worsening shortness of
breath. His symptoms were thought to be multifactorial
secondar y to communit y-acquired pneumonia,
sarcoidosis flare, and pulmonary edema. He was treated
with an increased dose of steroids, antibiotics, and diuretics
with symptomatic improvement. He was discharged on
40mg prednisone daily with a plan to taper as an outpatient.
Notably, CT scan on admission showed under-aerated lung
parenchyma via chest wall defects, consistent with bilateral
intercostal lung herniations [Figure 1]. He had known
longstanding right-sided lung herniation, and in 2010, it was
documented that he had recent development of left-sided
herniation as well. These were attributed to frequent
coughing spells related to his sarcoidosis. He was evaluated
by thoracic surgery, and due to his overall poor lung
function, surgical intervention was thought to be of little
potential benefit. Additionally, given his history of aspergillus,
surgical repair was thought to be a higher risk procedure
than usual, as repair often involves placement of a foreign
body (mesh). Lastly, he did not have much discomfort from
the hernias, and thus it was thought that there was a greater
risk from intervention rather than benefit.
Figure 1: Chronic lung changes of end-stage sarcoidosis with right mid-lung
abnormality corresponding to under-aerated right middle lobe lung parenchyma via
chest wall defect, also seen on left, secondary to chronic intercostal herniation of lung.

DISCUSSION
A lung hernia is an out-pouching of pulmonary
parenchyma through a defect in the chest wall. Lung
herniations can be classified based on etiology and
anatomical location (thoracic and cervical). Intercostal
herniations are classified as congenital (18%), acquiredtraumatic (52%), or acquired-spontaneous (30%). 1,2
These can develop due to increased intrathoracic
pressure with concurrent weaknesses in the chest wall.3
Symptoms include pain with inhalation, coughing, or
sneezing; shortness of breath; soreness; or swelling.
Long-term complications of lung hernias include
recurrent pulmonary infections and strangulation.2 Few
cases of bilateral thoracic lung herniations are
documented in the literature.4 Repair is often indicated in
cases with pain and entrapped lung.
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CARDIOLOGY

An Approach to Refractory Hypoxemia
Daniel Garrido, MD, Evan Nardone, MD, Mark Mallozzi, MD

INTRODUCTION
Oxygenation normally occurs through a process of
passive diffusion through the pulmonary capillaries,
where oxygen binds to hemoglobin or plasma. When the
oxygenation is deemed insufficient, a decrease in the
partial pressure develops, resulting in hypoxemia. This is
in contrast to hypoxia, which develops when there is a
low presence of oxygen at the level of the tissue.1,2 The
oxygenation of hemoglobin is most often measured
through the arterial oxygen saturation (SaO2), which
represents the proportion of hemoglobin that is bound
to oxygen in red blood cells. This is represented most
commonly through pulse oximetry, which is normally
>95% in healthy adults. 3 To accurately measure the
amount of oxygen dissolved in plasma, the arterial
oxygen tension (PaO2) is measured, which is represented
through an arterial blood gas (ABG).
One method to measure oxygenation is through the
calculation of the A-a oxygen gradient. This measure
identifies the difference between oxygenation within the
alveoli (PAO2), and within that dissolved in plasma (PaO2).
This gradient represents how well gas is exchanged
between the alveolar and capillary membranes. When
the difference in the A-a gradient (PAO2-PaO2) is normal
(<10mmHg), etiologies for respiratory failure are typically
from alveolar hypoventilation or low inspired FiO2.
However, when there is a widened A-a gradient, etiologies
may include ventilation-perfusion (V/Q) mismatch,
right-to-left shunting, or a diffusion defect.4 When in the
presence of oxygen there is no improvement in a patient's
hypoxemia, then the hypoxemia is deemed refractory.
Herein we present an unusual case of refractory
hypoxemia in a patient with patent foramen ovale (PFO)
and extensive deep vein thromboses (DVT).

hypoxemia including chest CTA, methemoglobin levels,
and autoimmune serologies, which were negative.
However, ABG persistently demonstrated 30% shunt
fraction. Transthoracic echocardiogram (TTE) with
bubble study was concerning for a PFO. Subsequent
transesophageal echocardiogram (TEE) confirmed an
ascending aortic aneurysm forcing the PFO open with
large and rapid right-to-left shunting. After presuming a
right-to-left shunt as the primary cause of hypoxemia, a
right heart catheterization (RHC) was performed with an
attempted PFO closure (as the patient was not a surgical
candidate). RHC demonstrated pulmonary arterial (PA)
pressures of 25mmHg/10mmHg. During the procedure
a left atrial clot was incidentally found and cleared with
catheter removal. However, intra-procedural closure of
the PFO resulted in hypotension and no improvement in
oxygenation. Given the left atrial clot and the discovery
of bilateral lower extremity DVT on ultrasound, a lung
perfusion scan was performed to evaluate for chronic
thromboembolic disease (as the patient could not
tolerate a ventilation scan), however the result was
normal. It was ultimately believed that her poor
oxygenation was due to her PFO with frequent changes
in the shunt due to position and hemodynamics. After a
goals of care discussion, the patient was transitioned to
comfort care and discharged on hospice.

DISCUSSION
We believe this case provides a good opportunity to work
through a differential for refractory hypoxemia. Despite
extensive testing, the ultimate etiology of the presented
patient’s hypoxemia was unclear at the time of her
discharge to hospice. Below we discuss the typical
differential for hypoxemia and apply it to the case above.
1.

CASE DESCRIPTION
A 74-year-old female with no significant pulmonary
history presented as a transfer from an outside hospital
for persistent refractory hypoxemia. ABG on admission
was noted to be pH 7.50, pCO2 25, pO2 58, and HCO3
of 20 while on 13L nasal cannula. She was noted to have
an A-a gradient >400. The patient was also noted to
desaturate to 70-80% O2 saturation with movement and
when sitting up (suggestive of orthodeoxia-platypnea
syndrome), which continued despite being transitioned
to high-flow nasal cannula and intermittent BiPAP
therapy. Extensive workup had been performed for her

Right-to-left shunt: During right-to-left shunting,
hypoxemia is caused by deoxygenated blood mixing
with oxygenated blood in the systemic circulation.
This can be from anatomic defects such as
intracardiac shunts (PFO, VSD, etc.), pulmonary AVMs,
or processes causing intrapulmonary vasodilation
(i.e. hepatopulmonary syndrome). Shunting can also
be physiologic during which non-ventilated lung are
perfused which can occur in pneumonia, ARDS,
atelectasis, etc. Typically, these patients have
hypoxemia, which is difficult to correct with
supplemental oxygen. Our patient had an appropriate
workup for intracardiac shunting and ultimately a
PFO was found on TEE. Furthermore, it was thought
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that her ascending aortic aneurysm was forcing her
PFO open in certain positions causing her to have
positional desaturations. Interestingly, however, when
her PFO was occluded during cardiac catheterization,
her oxygenation did not improve and ultimately
closure was aborted due to hypotension. It is unclear
why her oxygenation did not improve with occlusion
of her shunt.
2.

3.

V-Q mismatch: Some degree of perfusion and
ventilation mismatch occurs physiologically in the
healthy lung but is worsened in the diseased lung
state. Hypoxemia can occur by this mechanism when
there is a decrease in the ventilation or perfusion of a
lung segment impairing oxygenation of blood. In our
patient, given her extensive clot burden with left atrial
clot and bilateral lower extremity DVTs, it was thought
that pulmonary emboli may have been causing
defects in perfusion to her lung and contributing to
her hypoxemia. She was unfortunately unable to
tolerate a ventilation scan but had a perfusion scan
that was normal, making this etiology less likely.
Diffusion limitation: Hypoxemia by this mechanism
occurs when there is a diminished ability for oxygen
to diffuse from the alveolus to the capillary. It is
commonly due to interstitial lung disease causing
interstitial inflammation and fibrosis. Our patient did
not have findings on her chest imaging that were
indicative of interstitial inflammation. Additionally, she
had an extensive autoimmune serologic workup that
was negative. Hypoxemia by this mechanism is
commonly worsened by exertion and improved with
rest. Our patient had profound hypoxemia at rest
making this etiology less likely.

4.

Hypoventilation: During hypoventilation, both arterial
and alveolar CO2 increases which causes decrease in
alveolar oxygen tension. Hypoxemia due solely to
hypoventilation will have a normal A-a gradient, will
have primarily elevated PaCO2, and will rapidly
correct with increased FiO2. A typical presentation
may be a patient with obesity hypoventilation,
disorders causing respiratory muscle weakness, or
CNS depression. Our patient did not have evidence
of hypoventilation on her blood gas making this
etiology for hypoxemia less likely.

5.

Decreased fraction of inspired oxygen (FiO2): This
causes hypoxemia by decreasing the oxygen gradient
from the alveolus to the artery. This is typically
associated with high altitudes and not a likely etiology
for our patient given her history.
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Ultimately, it was decided that the most likely etiology of
our patient’s hypoxemia was due to right-to-left
intracardiac shunting, but it remains unclear why her
hypoxemia did not improve with PFO occlusion during
cardiac catheterization. Given her substantial lower
extremity clot burden and the presence of intracardiac
blood clots, it is possible that V/Q mismatch was also
contributing to this patient’s hypoxemia with intrapulmonary shunting. However, her right-sided and pulmonary
pressures on TTE and RHC did not show evidence of
pulmonary hypertension that would be expected in V/Q
mismatch due to chronic thromboembolic disease.
Although less likely, we cannot rule out this as a
contributing factor to her hypoxemia since she was not
able to tolerate a full V/Q scan. This case highlights an
atypical presentation with multiple possible etiologies of
hypoxemia and provides an opportunity to work through
a broad differential for this problem.
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CARDIOLOGY

Pericardial Effusion with Tamponade Physiology
in a Patient with Multiple Myeloma
Sairamya Bodempudi MD, Rukaiya Bashir Hamidu MD, Preya Simlote MD, Shuwen Lin MD,
Philip Margiotta MD, Tina Boortalary MD, Gregary D. Marhefka MD

Figure 1. (A) RA diastolic collapse showing evidence of early tamponade.
(B) Plethoric IVC from a subcostal view. (C) Circumferential shot from a
subcostal view to show the extent of the pericardial effusion.

INTRODUCTION

CASE PRESENTATION

Both solid and hematological malignancies are known
to cause pericardial effusions. The hematological
malignancies that most often cause pericardial effusion
are leukemias, Non-Hodgkin’s lymphomas, and
Hodgkin’s lymphomas. 1 Patients can also develop
pericardial effusions from cancer-related causes, such
as chemotherapy, immunotherapy, radiation, or
infection.2 Although it has been reported in the literature
(approximately 27 cases between 1970 to 2019),
malignant pericardial effusion from multiple myeloma is
relatively uncommon.3,4 In addition, a rare but known
complication of poorly controlled multiple myeloma is
hyperviscosity syndrome, which typically presents as
spontaneous hemorrhage of the mucosal membranes,
headaches or neurological symptoms. We present a
case of a patient with multiple myeloma who was found
to have a pericardial effusion with tamponade that was
also complicated by hyperviscosity syndrome.

History of Present Illness
A 78-year old African American female with a past
medical history of IgA Kappa Multiple Myeloma was
transferred to the Cardiovascular Intensive Care Unit
(CVICU) at Thomas Jefferson University Hospital (TJUH)
after being diagnosed with a pericardial effusion with
tamponade physiology at an outside hospital.
The patient was diagnosed with multiple myeloma 3
years prior on a left maxillary biopsy revealing a
plasmacytoma. Due to medical complications, multiple
hospitalizations, poor follow up, and intermittent refusal
of chemotherapy, the patient never achieved remission
of her malignancy. Due to continued progression of her
disease, she was started on Melphalan /methylprednisolone therapy and had finished 5 cycles.
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The patient was in her usual state of health until one
week prior to presentation when she developed a cough
and dyspnea on exertion. Since her symptoms
progressed, she eventually went to the emergency
department, where she was noted to have a pericardial
effusion with signs of early tamponade physiology. She
was transferred to the CVICU at TJUH for further care.
Upon arrival to TJUH, the patient was tachycardic with
heart rates in the 110s. A physical exam revealed
jugular venous distension, normal S1 and S2 heart
sounds, slight end expiratory wheezing throughout
the lung fields, and a droopy right eyelid with nodules.
A pulsus paradoxus was found to be 5 mm Hg and a
bedside transthoracic echocardiogram (TTE) showed
a circumferential pericardial effusion with a maximum
size of 2.2 cm, brief right atrial diastolic collapse, and
a non-compressible inferior vena cava concerning for
early tamponade physiology.

Hospital Course
Due to concern for tamponade, the patient received a
pericardiocentesis with pericardial drain placement.
Approximately 185 mL of sanguineous fluid was drained
and sent to the lab for typical studies, including cytology
plus flow cytometry. A repeat TTE showed trivial residual
pericardial effusion with improved hemodynamic profile
and resolution of tamponade. Pericardial fluid cytology
and flow cytometry results showed evidence of plasma
cells consistent with her underlying plasma cell myeloma.
Within a day of admission, the patient developed
significant interval swelling of her right eye with
ecchymosis of her medial upper eyelid and significant
conjunctival hemorrhage. Due to subjective shortness of
breath, a chest radiograph was done and showed the
correct positioning of the pericardial drain. However, it
incidentally showed new left sided pleural effusion. Given
multiple sites of spontaneous hemorrhage and
significantly elevated IgA levels (>4500), there was
concern for hyperviscosity syndrome. Medical oncology
was consulted and recommended urgent plasmapheresis,
however, the patient initially refused conveying her wishes
to pursue non-aggressive medical therapy. She was
temporized with intravenous fluids and high-dose steroids.
On day 7 of post-pericardial drain placement, there
continued to be high output (>75mL/day) from the
drain. Given the increased risk of infection with
prolonged drain placement and continued high output
in the setting of hyperviscosity syndrome, the decision
was made for doxycycline sclerotherapy to the
pericardium with subsequent removal of the pericardial
drain. Repeat TTE the following day showed only trivial
pericardial effusion.

10 | The Medicine Forum, Volume 21

5

Eventually, the patient consented to plasmapheresis,
resulting in a downtrend of her IgA level. She received
cytoreductive chemotherapy with cyclophosphamide
and dexamethasone. The patient’s post-chemotherapy
hospital course was complicated by paroxysmal
supraventricular tachycardia, acute kidney injury, stressinduced hyperglycemia requiring insulin therapy and
febrile neutropenia from an unknown infectious source.
T h e s e co m p l i c at i o n s re s o l ve d w i t h m e d i c a l
management.
Prior to discharge, goals of care were readdressed.
Although initially hesitant, the patient and her family
ultimately decided to pursue aggressive treatment of
her multiple myeloma. She was subsequently
discharged to a sub-acute rehabilitation center after
which she under went chemotherapy with
daratumumab, pomalidomide, and dexamethasone.
Two months after the patient’s initial presentation to
the TJUH CVICU, the patient is doing well on her
current chemotherapy regimen with down trending IgA
levels. She has stable pleural effusions on chest x-ray.
Repeat TTE’s show no evidence of pericardial effusion.
She remains symptom free with no further medical
complications.

DISCUSSION & CONCLUSIONS
As stated previously, pericardial effusions secondary to
multiple myeloma are very rare, seen in < 1% of cases.4
Although in our case, the pericardial fluid was determined
to be malignant in origin based on flow cytometry and
cytology, the rapid re-accumulation of pericardial
effusion almost a week after drain placement was
presumed to be due to the spontaneous bleeding
complications of hyperviscosity syndrome. The medical
interventions were unique for this particular patient due
to her preference of treatments. She was initially
temporized with fluids and dexamethasone instead of
immediately being star ted on plasmapheresis.
Interestingly, temporizing measures did initially slow the
rate of drain output.
Despite stabilizing with steroids and fluids, the patient’s
re-accumulating pericardial effusion necessitated
management with sclerotherapy. Per review of literature,
doxycycline sclerotherapy for recurrent pericardial
effusions secondary to multiple myeloma has not been
performed.4 The decision to attempt bedside doxycycline
sclerotherapy highlights the role of shared-decision
making between the patient, her family, cardiology,
medical oncology, and thoracic surgery in order to
respect the patient’s wishes to opt for minimally invasive
treatment strategies.

Our case also explores the complicated relationship
between management of plasma cell pericardial
effusions and hyperviscosity syndrome, which may
increase the risk of bleeding into the pericardium. When
the patient is clinically and hemodynamically stable, and
willing to receive plasmaphoresis, it is reasonable to treat
the hyperviscosity syndrome prior to draining the
pericardium to decrease the risk of post-intervention
bleeding. However, when a patient presents with early
signs of tamponade physiology or hemodynamic
instability, then a pericardiocentesis could be considered
and prioritized with simultaneous temporization of
hyperviscosity syndrome utilizing high-dose steroids and
fluids as we had done in this case. Finally, the case
demonstrates that it is essential to intermittently revisit
goals of care because our patient’s wishes evolved and
molded her medical management. On-going discussions
resulted in her changing her initial decision, and altering
the course of her disease process. Our case of a patient
with multiple myeloma presenting with malignant
pericardial effusion as an extra-medullary manifestation
of chemotherapy-refractory multiple myeloma is
therefore unique from a clinical presentation, medical
intervention, and a shared decision-making standpoint.
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GASTROENTEROLOGY & HEPATOLOGY

Diagnosing Non-HFE Hereditary Hemochromatosis
Brian Park, MD, Naman Upadhyay, MD, Dina Halegoua-Demarzio, MD

ABSTRACT
Non-HFE hemochromatosis is a rare cause of end stage
liver dysfunction that is characterized by excessive iron
deposition in the liver. The vast majority of primary iron
overload is due to well documented mutations of the
HFE genetic locus, however, rare genetic cases not
involving the HFE locus have been documented. Here
we present the case of a 63-year-old female who
developed liver failure due to non-HFE hemochromatosis. Secondary causes of iron overload were ruled
out, and genetic testing was negative for primary HFE
(C282Y and H63D) mutations. We discuss the clinical
work up involved in making the diagnosis of non-HFE
hemochromatosis and the treatment options.
Keywords: Non-HFE Hemochromatosis, primary
hemochromatosis, iron overload, hereditary hemochromatosis

INTRODUCTION
Hereditar y Hemochromatosis (HH) is a disease
characterized by increased intestinal absorption of iron
and subsequent deposition in tissues. Hemochromatosis
is a progressive disease that without therapeutic
intervention can lead to iron accumulation in tissues
leading to organ damage such as liver cirrhosis, diabetes,
skin discoloration, and cardiomyopathy1.
Primary hemochromatosis due to the HFE gene is the
most common identified genetic disorder in Caucasians
of northern European descent with a prevalence of 1 in
200 individuals and accounting for 60-95% of European
iron overload cases2. In contrast, most cases of iron
overload that do not involve the HFE gene are due to
secondary hemosiderosis. However, there are rarely
observed gene mutations that result in primary
hemochromatosis collectively called non - HFE
hemochromatosis3.

CASE REPORT
A 63-year-old Caucasian female presented for evaluation
of abnormal bile duct appearance on ERCP after being
diagnosed with gallstone pancreatitis, duodenal ulcers
and gastritis at another hospital. Over the past several
years she had noticed increasing fatigue, unintentional
weight gain of 30 pounds, lower extremity and abdominal
swelling. The patient recalls having jaundice at the age of
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14, and at age 28 she was told she had hepatitis although
her hepatitis testing was negative. She has a history of
psoriasis and vitiligo. Her family history is notable for liver
disease of unknown etiology in her grandmother,
gallbladder and thyroid disease in her mother, daughter
with psoriasis, and son with type 1 diabetes mellitus.
She rarely drinks alcohol. She has taken an occasional
Aleve for arthritic pains but had not taken any NSAIDs in
two years. She does not smoke cigarettes or use illicit
drugs. She worked at a large wholesale grocery as a
door greeter.
Her physical exam was notable for prominent scleral
icterus, diffuse jaundice, abdominal distension with
dullness in flanks but no tenderness, 3+ pitting edema in
bilateral lower extremities, chronic vitiligo of hands and
chest, palmar erythema, asterixis with mild confusion,
but no spider angiomas or malar rash.
Her labs were significant for iron overload with iron
saturation of 95%, elevated ferritin of 4400 ng/mL,
decreased transferrin to 138 mcg/dL, and iron level
elevated to 185 mcg/dL. She had a macrocytic anemia
with hemoglobin of 9.0 g/dL, MCV 108 and normal B12
and folate.
Labs were negative for CMV, EBV, VZV, HAVAb, HBGAg,
HBVAb, HCVAb, and HIV. Normal AFP (3.7 ng.mL), A1AT
(14 mg/dL), TSH (3.4 uIU/mL), A1c 4.1, and low normal
ceruloplasmin (19mg/dL). Presenting MELD-Na score
was 17 (Cr 0.6, Bili 4.9, INR 1.5, Na 140).
Elevated IgG, but negative ANA and ASMA (ruling out AIH
and PBC). Gene mutations for primary HFE (C282Y and
H63D) were negative.
MRI (Figure 1) was consistent with primary hemochromatosis effecting the non-reticuloendothelial system
(non-RES); involving the liver, but not the spleen or bone
marrow. Additionally, on the dual-sequence MRI
(Figure 2) there is a drop in signal intensity on the image
with the longer echo time10.
Liver biopsy (Figure 3) demonstrated bridging fibrosis
and focal nodularity, stage 3-4. Features of chronic
hepatitis evidenced by mild lobular and portal
inflammation. Iron stain showing 4+ hepatocellular iron
deposit. No evidence of steatohepatitis. No evidence of
portal edema or brisk ductular reaction to support biliary
obstruction.
Despite treatment her condition progressed to ESLD and
she was listed with successful liver transplantation.

Figure 2: Dual sequence MRI “In Phase and Out of Phase” showing decreased signal
of the liver on the “In Phase” image (left) compared to “Out of phase” image (right)
which is consistent with hemochromatosis. The iron deposition is more severe
in the liver.

Figure 1: Figure 1: T2 weighted MRI showing decreased enhancement of the liver
(darker appearance) but not the spleen, characteristic in iron overload due to primary
hemochromatosis.

DISCUSSION
Hereditary Hemochromatosis (HH) is a disease of iron
overload that is most commonly due to mutations of the
HFE gene. The HFE gene mutation most commonly
involves a tyrosine for cysteine substitution at amino acid
position 282, or protein product C282Y1 . The allele
frequency of C282Y is close to 5% in European
populations according to the 1000 Genomes Project
and explains the large number of European persons with
primary hemochromatosis who are homozygous for
C282Y HFE gene2.
Rarely, there are cases of iron overload consistent with
primary hemochromatosis that do not involve the HFE
gene collectively called non-HFE hemochromatosis3.
These non-HFE genes include hemojuvelin (HJV),
hepcidin (HAMP), transferrin receptor (TFR2) and
ferroportin (SLC40A1). Though most known forms of
primary hemochromatosis have recessive inheritance,
SLC40A1 is recognized as a rare autosomal dominant
inherited genotype that can be associated with a splicing
mutation4. These gene mutations have phenotypes that
range from the severe juvenile forms of iron overload as
in mutations of HJV and HAMP to the milder phenotypes
associated with TFR2 and SLC40A15. Typically, the earlier
onset forms involve severe endocrine and cardiac
manifestations that can result in death by the age of 305.
Notably, ferroportin mutations were first described in
1999 in individuals of Italian and Dutch descent, but
were later observed in gene sequencing of Asian,
American and African populations6,7.
The diagnosis of non-HFE hemochromatosis involves
ruling out secondary causes of iron overload, quantifying
liver iron stores via MRI or liver biopsy, determine the
hereditary nature of the iron overload by genetic testing
(typically for HFE only)8. As mentioned previously, MRI

Figure 3: Iron stain from our patient showing 4+ hepatocellular iron deposition (left
blue stain). H&E stain demonstrated bridging fibrosis and focal nodularity, stage 3-4
(right pink stain) Features of chronic hepatitis evidenced by mild lobular and portal
inflammation.

did not show involvement of spleen or bone marrow
whereas for hemosiderosis or secondary hemochromatosis, iron deposition would be prominent in these
locations.
Estimates of the prevalence of non-HFE hemochromatosis
were previously about 10%6. To date, 55 HJV cases, 13
HAMP cases, 49 TFR2 cases, and 60 cases of SLC40A1
disease have been reported7. Next-generation sequencing
supports the rarity of these non-HFE pathogenic alleles
with predicted frequencies ranging from 0.00007 to
0.0004. Compare this to the 5% allele frequency of the
C282Y missense substitution as previously noted.
Corresponding predicted frequencies of the genotypes
range from 1 in 556 for SLC40A1 to 1 in 6,000,000 for
TFR2 and as rare as 1 in 181,000,000 for HAMP7.
Heterozygous mutations in SLC40A1 lead to ferroportin
disease and we were surprised to find relatively high
frequencies of SLC40A1 variants classified as pathogenic.
These variants were found at the highest frequencies
among African populations (0.25%) but were also present
in the American (0.039%), East Asian (0.033%), and
non-Finnish European (0.03%) populations7. Non-HFE
HH seems to be more prevalent in southern Europe
compared with northern Europe.
Due to the lack of widely available direct gene
sequencing, these non-HFE genes are not recommended
to be tested unless investigating severe refractory cases8.
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An Unusual Treatment for
Chronic Myelomonocytic Leukemia
Eric Warner, MSIII, Neil Palmisiano, MD

ABSTRACT
Chronic myelomonocytic leukemia is a rare, aggressive,
chronic leukemia that frequently progresses to acute
myeloid leukemia. For younger patients, treatment
ideally involves bone marrow transplant, and, if not a
candidate, hydroxyurea or hypomethylating agents are
the standard of care for symptomatic patients. Here, we
present an unusual treatment of a patient with chronic
myelomonocytic leukemia (CMML) characterized by
atypical mutations in IDH2 and NPM-1 using Venetoclax
and a hypomethylating agent with complete response.

INTRODUCTION
Chronic myelomonocytic leukemia has features of both
myelodysplastic syndrome and myeloproliferative
neoplasms. Characterized by an increase in circulating
monocytes, the disease frequently progresses to acute
myeloid leukemia (AML) and is the most aggressive
chronic leukemia. Clonal cytogenetic abnormalities are
found in approximately 30% of patients, most commonly
trisomy 8, trisomy 21, monosomy 7 and del7q, and other
complex karyotypes.1 For younger, fit patients, treatment
ideally involves bone marrow transplant. If not a
candidate, cytoreductive strategies using hydroxyurea
or hypomethylating agents (HMA) are the standard of
care for symptomatic patients. Because of the rarity of
this disease, advancement of treatment strategies outside
of transplant have been few. 2 This case is presented to
demonstrate an unusual treatment for CMML with IDH2
mutation using Venetoclax and an HMA.

CASE PRESENTATION
A 76-year-old female with a past medical history of an
extraosseous chondrosarcoma status-post resection
thirty years prior, hypertension, hyperlipidemia, and
hypothyroidism presented to her primary care physician
with fatigue, two weeks of dyspnea on exertion,
lightheadedness, and nausea. The patient’s primary care
physician ordered a complete blood count, which was
significant for a hemoglobin of 6.8 g/dl and she was
instructed to go to the Emergency Room for workup. In
the ER, the patient was afebrile, and her vital signs were
all within normal limits. On exam, she was noted to have
a 3/6 systolic ejection murmur. Her lungs were clear to
auscultation bilaterally and she did not have any skin
abnormalities. She was given a transfusion of packed red

blood cells and her hemoglobin responded appropriately.
However, she was found to have thrombocytopenia and
a leukocytosis with an absolute monocyte count of
5800 cells/uL (16% of the differential), a total white blood
cell count of 36,400 cells/uL, a platelet count of 52,000
per/uL and no eosinophilia.
After being discharged, the patient was seen by oncology
and underwent a bone marrow biopsy. Pathology
showed hypercellular marrow (95%) with trilineage
proliferation, 10% monocytes and 5-10% blasts with less
than 10% dysplasia. Flow cytometry, cytogenetics and
Next-Generation Sequencing were unable to be
performed due to an inadequate sample. Peripheral
blood was then analyzed which showed 16% monocytes,
7% blasts and flow cytometry positive for CD4, CD11c,
CD13, CD33, CD34, CD38, CD64, HLA-DR and CD117.
Cytogenetics showed a normal female karyotype and
was negative for BCR/ABL rearrangement. Mutational
analysis was positive for IDH2, DNMT3A and NPM1 and
was negative for JAK2, CALR and MPL. She was
subsequently diagnosed with CMML, given her monocytic
predominance and flow cytometry. Due to her excellent
functional status (ECOG score of 1), curative treatment
with cytoreductive agents and bone marrow transplant
was pursued. Because of her NPM-1 and IDH2 mutation,
it was decided that a regimen consisting of Decitabine
and Venetoclax was appropriate. She began treatment in
early February 2019 and, after two cycles, a biopsy was
repeated, which showed only 9% abnormal myelocytes
and no blasts. The regimen was well-tolerated by the
patient and by June she was in complete response (CR)
with no complications from treatment. She underwent
another biopsy prior to transplant which showed
hypocellular marrow with less than 1% monocytes and
blasts. She then underwent non-myeloablative bone
marrow transplant in November and, as of last follow-up
112 days later, is in recovery. Bone marrow biopsy
post-transplant showed normocellular marrow with no
increase in abnormal monocytes.

DISCUSSION
Chronic myelomonocytic leukemia is diagnosed based
on a peripheral monocyte count above 10%, in addition
to bone marrow dysplasia. It frequently progresses to an
acute leukemia in up to 20% of cases.3 The median age at
onset is during the early seventh decade of life, and it has
a slight male preference. There are several classification
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systems including the World Health Organization classification and the Mayo prognostic model, however the most
commonly used is the CMML-specific prognostic scoring
system (CPSS). The CPSS classifies patients into various risk
categories using their CMML FAB type, cytogenetics, red
blood cell transfusion dependence and, WHO subtyping
based on the percentage of blasts in the periphery and
bone marrow. For low risk patients the median survival is
6 years, for high risk patients it is just 5 months.1
The most common mutations in CMML have differing
mechanisms, including epigenetic control of methylation
(TET2 60%), chromatin modulating (ASXL1 40%), cell
signaling pathways (RAS pathway 30%) and mRNA splicing
(SRSF2 50%). ASXL1 has been shown to correlate with
survival. Mutations in IDH1 or IDH2 are uncommon in
CMML, occurring in less than 5% of patients.4 Although
rare in CMML, approximately 15% of patients with AML
have a mutation in IDH. Normally IDH is involved in the
citric acid cycle and metabolizes isocitrate to 5-alphaketoglutarate. When IDH is mutated, it gives rise to a new
metabolic product: 2-hydroxyglutarate (2-HG). 2-HG
accumulates and inhibits other enzymes including TET2
and JMJC, both epigenetic modifiers that can lead to
leukemogenesis.5 Cells following this pathway become
dependent on the anti-apoptotic gene Bcl-2 for survival.6
Due to its association with epigenetic dysregulation, the
standard of care for CMML is a hypomethylating agent,
specifically azacitidine or decitabine. These medications
work by demethylating and subsequently allowing
expression of hypermethylated tumor suppressor genes.7
Unfortunately, only 50% of patients respond to these
agents, with less than 20% achieving complete response
to these agents alone.1 HMAs are also frequently used in
patients with AML who are not candidates for standard
chemotherapy induction. Unfortunately, response rates in
most studies of patients with AML show a complete
response in only approximately 20%.8 In more recent
studies, patients over the age of 65 with AML were given
the Bcl-2 inhibitor Venetoclax in addition to an HMA.
Twenty-four percent of these patients achieved CR, with
an additional 43% achieving CR with incomplete cell
count recovery.9 To our knowledge, there have been no
studies using HMAs plus Venetoclax in patients with
CMML, however, Venetoclax has been shown to have
efficacy in CLL, AML, and ALL, particularly in patients with
IDH mutations.10 Although this is a relatively rare mutation
in CMML, further study of this treatment regimen is
warranted in patients who express IDH mutations in
CMML and other MDS/MPNs.
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A Case Report of Hemophagocytic
Lymphohistiocytosis Secondary to
Disseminated Tuberculosis
Shuwen Lin, MD, Christopher Terry, MD

INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is a
life-threatening disorder characterized by excessive
activation of the immune system causing tissue damage
and organ dysfunction. Secondary HLH is more
common in adults and is usually triggered by infection,
malignancy, rheumatologic, and immunodeficiency
syndromes. We present a case of HLH secondary to
disseminated tuberculosis (TB).

CASE PRESENTATION
A 72-year-old woman with past medical history of
hypertension and type 2 diabetes presented to the
emergency department for one day history of fevers,
poor oral intake, and fatigue. She was febrile to 102.9 F
and noted to have a toxic appearance, but there were no
focal abnormalities found on exam. Initial blood work was
notable for a mild direct hyperbilirubinemia of 2.5mg/dL,
AST/ALT of 162/112 IU/L and elevated INR of 1.4. Abdominal
ultrasound showed gallbladder wall thickening. Due to
concerns for ascending cholangitis, ERCP was performed
and revealed a normal biliary system. Day 2 of hospitalization revealed new pancytopenia - her white blood cell
count was 2.7 B/L with 44% bands, hemoglobin was 10.8
g/dL, and platelet count was 39 B/L. She also had rising
hepatic function tests. Her ferritin on day 3 was
significantly elevated at 4149 IU/L, raising concerns for
HLH. On day 4, the patient became increasingly
tachypneic and tachycardic with radiographic findings of
pulmonary edema despite diuresis, as well as acute kidney
injury with decreased urine output. She was intubated for
increased work of breathing. Due to a high suspicion of
HLH with the probability of HLH greater than 99%
calculated by the HScore, methylprednisolone 120mg
daily in split doses was initiated. Etoposide was not started
due to her multiorgan dysfunction. On day 5, her liver and
kidney failure worsened, and her ferritin and triglycerides
continued to rise. She also developed hypofibrinogenemia concerning for DIC. On day 6, methylprednisolone was changed to dexamethasone 8mg Q6 and
anakinra 100mg Q12 was added, but this was discontinued
on day 7 when her liver biopsy showed many caseating
and non-caseating granulomas with AFB stain positive for
acid-fast bacilli. Sputum AFB stains were also obtained

positive for acid fast bacilli. Sputum PCR showed
Mycobacterium tuberculosis (TB) leading to the
presumptive diagnosis of HLH secondary to disseminated
TB. Due to the patient’s acute liver failure, a modified
regimen of TB treatment was initiated including rifampin,
ethambutol, levofloxacin, and amikacin. Despite TB
treatment, immunosuppression for HLH, and supportive
measures, the patient continued to deteriorate and
expired on day 10.

DISCUSSION
Although HLH secondary to TB (TB-HLH) has previously
been reported in the medical literature, it remains a rare
entity.1 Most patients with TB-HLH had short symptom
duration and rapid progression leading to multi-organ
dysfunction and ultimately, death.
The first HLH treatment protocol was published in 1994
(HLH-94) and has been widely used in clinical practice.
HLH -94 includes an anti - inf lammator y agent ,
dexamethasone, and a pro-apoptotic agent, etoposide.
This regimen has been shown to improve survival but was
primarily based on data in the pediatric setting, many with
primary HLH.2 Furthermore, etoposide was not determined
to be a safe option due to her multi-organ dysfunction.
Instead, anakinra, an IL-1 receptor antagonist was used in
combination of dexamethasone. Anakinra as an immunomodulator has also been shown to be effective in the
treatment of severe HLH in the critical care setting. 3-4
Additionally, secondary HLH is often triggered by an acute
infection or other condition (eg, rheumatologic condition)
and treatment should be to address the underlying cause
of immune activation. Although there is no consensus of
standard treatment for TB-HLH, a systematic review of
the international literature demonstrates that a delay or
absence of antitubercular therapy (ATT) were associated
with decreased survival.5 On the contrary, the combination
of antitubercular therapy (ATT) with immunotherapy has
been found to significantly reduce mortality.1 Our patient
was initiated on a modified regimen of ATT as soon as the
diagnosis of disseminated TB was made, but she still
passed several days later. This case highlights the need for
ongoing investigation for early detection and management
of secondary HLH in the adult setting.
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Exploring the Adverse Effects of CAR-T Therapy:
A Case Report of Potential MINOCA in CAR-T
Danielle Verghese, PGY-1, Adam Binder, MD, Colin Thomas, MD

INTRODUCTION
The discovery and application of Chimeric Antigen
Receptor T-Cell Therapy (CAR-T) has marked a new era
in cancer treatment. CAR-T is a novel therapy with a
relatively small treatment population, and we have yet
to identify the full spectrum of its adverse effects. 1
There are well-established approaches to the most
common adverse effects, principally cytokine release
syndrome (CRS), but there is limited literature discussing
the nature of cardiotoxicity in CAR-T, much less its
mechanism or management. 2, 3 This case study
discusses the development of myocardial infarction
with no obstructive coronary atherosclerosis (MINOCA)
in a patient treated with CAR-T.

CASE PRESENTATION
A 48-year-old man with a history of Stage IV Diffuse
Large B- Cell Lymphoma refractor y to R- CHOP
alternating with high-dose methotrexate and cytarabine,
craniospinal irradiation, and haploidentical stem cell
transplant, underwent CD 19-directed CAR-T. His
post-treatment course was complicated by marrow
aplasia and infection, but he ultimately responded to
therapy and achieved complete remission.
Five months after undergoing CAR-T, the patient
presented with persistent malaise and vague abdominal
pain. Initial assessment found him to be cachectic and
frail, and he was admitted for further investigation of
failure to thrive (FTT). An extensive workup of endocrine,
metabolic, and infectious causes of FTT was unrevealing.
Labs showed stable neutropenia (ANC 0.4) and anemia
(Hgb 9.7) with no evidence of adrenal insufficiency,
thyroid dysfunction, vitamin deficiencies, nor bacterial,
viral, or fungal infections. EGD did not reveal any
significant gastrointestinal pathology, only patches of
chronic, mild inflammation.
On the sixth day of hospitalization, the patient reported
left shoulder pain. Telemetry showed an acute increase
in heart rate, from a baseline sinus tachycardia of 100-110
bpm to 130-140 bpm. EKG revealed new inferior ST
segment elevations. Echocardiography identified newly
depressed ejection fraction (45%) and basal to

mid-anterior and anteroseptal wall motion abnormalities,
where previous studies had shown normal EF and no
segmental wall motion abnormalities. High-sensitivity
troponins were elevated and continued to rise from –
344 ng/L followed by 366 ng/L in the setting of normal
renal function. Subsequent cardiac catheterization
revealed no obstructive coronary artery disease.
Altogether, the evidence for myocardial injury in the
absence of obstructive coronar y arter y disease
culminated in a diagnosis of MINOCA.
A multi-disciplinary team including Cardiology and
Hematology-Oncology reviewed possible etiologies of
cardiac injury. Although the patient had previously
received doxorubicin chemotherapy (total of 229 mg, 20
months prior to this admission), the acute onset of ST
elevations and dynamic troponins were atypical for
anthracycline-induced cardiomyopathy.4 Similarly, the
presentation was not typical for stress-induced cardiomyopathy, especially in the absence of an acute trigge.5
The constellation of cardiac findings was attributed to
myocarditis, but the underlying cause remained unclear.
The patient was not taking any medications commonly
associated with myocarditis. Infectious workup was
negative including blood cultures, urine cultures,
influenza A and B, respiratory pathogen panel, EBV, CMV,
tuberculosis and aspergillus testing. Of note, testing for
coxsackie A and B, HIV, and HSV was not performed.
Previous reports have posited a CRS-mediated
mechanism of cardiac injury in CAR-T, but CRS typically
peaks days after treatment, and would be uncommon
months after CAR-T infusion. 6 Another proposed
mechanism considers off-target cross-reactivity, leading
to an autoimmune myocarditis.6 The next best steps to
workup myocarditis would have been further infectious
testing, cardiac MRI, endomyocardial biopsy, but these
were deferred as the patient was high-risk for invasive
procedures and the findings were unlikely to change
clinical management.
Besides myocarditis, other etiologies of MINOCA include
coronar y vasospasm, coronar y microvascular
dysfunction, and thrombophilia7. These were not further
investigated during the patient’s hospitalization.
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A Case Report Of Tragaxofusp Causing Severe
Tumor Lysis Syndrome In A Patient With Blastic
Plasmacytoid Dendritic Cell Neoplasm
Shuwen Lin, MD, Alice Wang, MD

INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is
a rare and aggressive hematologic malignancy that
does not respond to cytotoxic chemotherapies well. We
present a case of BPDCN that was treated with a new
targeted therapy tagraxofusp and the fatal complication
that the patient developed with this treatment.

HOSPITAL COURSE
The patient was an 83-year-old male without significant
past medical history who presented to his primary care
physician with several days of generalized malaise. He
obtained routine bloodwork which showed a
leukocytosis to 29 B/L. He then presented to the ED for
further evaluation. Vitals were within normal limits and
physical exam was remarkable for splenomegaly. Labs
were significant for a WBC 44.7 B/L, Hgb 10 g/dL,
platelets of 96 B/L, and the differential showed 20.6 B/L
blasts. Creatinine was increased from a baseline of 1.20
to 1.45mg/dL, potassium was 4.9mmol/L, phosphate
was 3.1mg/dL, calcium was 8.5 mg/dL, lactate
dehydrogenase was 2705 IU/L, and uric acid was 5.1mg/
dL. A peripheral smear was done which showed
immature leukocytes with blastic morphology. He was
admitted for further hematologic malignancy workup.
Flow cytometry of the peripheral blood showed a
population that was CD4+, CD7+(dim), CD33+(dim),
CD38+(partial, bright), CD56+(partial, bright), CD 123+,
HLA-DR+(bright) and a monoclonal CD5+CD23+ B cell
population. These markers show an undifferentiated
blast population specific for neither lymphoid nor
myeloid lineage. Fluorescence in-situ hybridization (FISH)
showed 17p (TP53) deletion, 13q deletion (D13S319 and
LAMP1), and ZRSR2 mutations. A complete karyotype
revealed multiple complex chromosomal abnormalities
with the presence of two unrelated abnormal clones
suggesting genomic instability as well as the clonal
evolution of neoplastic cells. Bone marrow biopsy
showed hypercellularity and 84% immature-appearing
cells. The abnormal cells had following phenotype:
CD4+, CD10, CD13-, CD14-, CD16-, CD33+ (partial, dim),
CD34-, CD38+, CD56+ (partial), CD64-, CD117- ,
HLA-DR+. These immature cells express CD123 and were

negative for MPO by peripheral blood flow cytometry.
By immunohistochemistry, the neoplastic cells were
positive for CD4, CD43, CD56 (dim, partial), and TCL-1
(diffuse and strong). Notably, they were negative for
CD68, CD163, lysozyme, and MPO. These findings are
consistent with the diagnosis of blastic plasmacytoid
dendritic cell neoplasm (BDPCN). Additionally, flow
cytometry detected a small monoclonal B-cell population
(6%) with phenotype consistent with chronic lymphocytic
leukemia/small lymphocytic lymphoma. Further
assessment by computed tomography (CT) of the
abdomen and pelvis revealed massive splenomegaly to
23cm but did not show evidence of metastatic disease or
lymphadenopathy in the chest, abdomen, and pelvis.
The patient was subsequently started CD123 targeted
therapy with tagraxofusp at a dose of 12 mcg/kg three
days after admission. His lab values remained stable
from admission to initiating therapy. On cycle 1. day 1,
approximately 6 hours after he finished his first infusion,
the patient was found to have altered mental status with
increasing dyspnea and tachypnea to 50’s with
desaturation to 80% on room air. Labs obtained at the
time showed a WBC 130.5 B/L, Hgb 9.5g/dL, platelets of
102 B/L, and the differential showed 117.5 B/L blasts. His
creatinine was 2.11mg/dL, potassium 7.4mmol/L,
phosphate 10.9mg/L, LDH 20119 IU/L, and urate of
5.8mg/dL. The patient was placed on non-invasive
positive pressure ventilation and diuresis was given
without significant improvement. The decision was
made to intubate and he was transferred to the medical
intensive care unit. The patient’s acute hypoxic respiratory
failure was thought to be due to a combination of
capillary leak syndrome and tumor lysis syndrome
resulting in anuric acute kidney injury and fluid retention.
After his arrival to the intensive care unit, the patient was
febrile with temperature 102.4 F, hypotensive with BP
111/33, and bradycardic to 51 BPM. He was given more
diuresis with IV furosemide 100mg and started on
vancomycin and cefepime. Telemetry showed changes
consistent with hyperkalemia including peaked T-waves
and bradycardia. Temporizing measures were given
including insulin, dextrose, and bicarbonate infusion.
However, he ultimately required continuous veno-venous
hemodialysis (CVVHD) due to the severity of his
electrolyte derangements. During the patient’s ICU
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In our patient’s case, he developed an overwhelming
response to the tragaxofusp immediately after his first
dose. His anuric acute kidney injury secondary to tumor
lysis syndrome led to metabolic derangements, cardiac
instability and death. As potential adverse effects are not
fully known for this new agent, we suggest that this case
should raise awareness of the potential severity of tumor
lysis syndrome with tagraxofusp. In addition, cytoreduction
could be considered prior to the start of tagraxofusp in
patients with high tumor burden to decrease the risks of
developing tumor lysis syndrome.

course, he developed seizure-like activity. CT of the
head was negative for any acute changes such as edema
or hemorrhage. An electroencephalogram (EEG) was
done but was negative for seizure activity. The patient
then developed shock liver with elevations in AST 2859,
ALT 2205, ALP 108, and had a lactate of 11.9. He also had
multiple episodes of supraventricular tachycardia with
heart rates up to 170 BPM, which required adenosine
and cardiac resynchronization therapy. Due to the
severity of the patient’s condition and the wishes of the
patient’s family, aggressive care was stopped and the
patient’s care was switched to comfort measures only.
He passed away on cycle 1, day 4, after a palliative
extubation.
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BPDCN is an aggressive hematologic malignancy. One of
the characteristics of this malignancy is that the neoplastic
cells almost always overexpress interleukin-3 receptor
subunit alpha (IL3RA or CD123). Tagraxofusp, as a
CD123-directed cytotoxin consisting of recombinant
human interleukin-3 fused to a truncated diphtheria toxin,
targets this overexpression specifically. 1 In 2019, a
nonrandomized, multistage, open-label, multicenter
evaluation of tagraxofusp as monotherapy in patients with
BPDCN study was published in the NEJM and a 90%
overall response rate was observed among patient with
previously untreated BPDCN, and the majority of
responses were complete remission. In contrast, prior to
the development of tagraxofusp, there was no standard
treatment for BPDCN. BPDCN was treated with cytotoxic
chemotherapy regimens that were conventionally used
for treating acute lymphoblastic leukemia/large B cell
lymphoma, non-Hodgkin lymphoma, or acute myeloid
leukemia but with very limited success. Although the
standard-of-care remains untested in randomized fashion,
tagraxofusp exhibits a higher rate of complete responses
when used in the first-line setting. Because of this
presumed efficacy and his advanced age putting him at
higher risk for intensive induction chemotherapy, we
chose tagraxofusp as our therapy of choice.
The most serious adverse events of tagraxofusp that has
been reported is capillary leak syndrome.2 Capillary leak
syndrome is characterized by leakage of intravascular
fluids into the extravascular space, leading to generalized
edema, pulmonary edema and multiorgan failure. In the
Pemmaraju et al study, 9 patients (19%) had capillary leak
syndrome of various grade and two deaths that were
attributed to capillary leak syndrome. Tumor lysis
syndrome was also described as a less common and less
severe adverse event of tagraxofusp in this study. In total,
11% of the patients had ≥ grade 3 tumor lysis syndrome.z
However, no deaths were reported to be associated with
tumor lysis syndrome.
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INFECTIOUS DISEASE

A Case Report of Bullous Subconjunctival
Hemorrhage in Adenoviral Conjunctivitis
Sean Haynie and Jesse Johnson, MD

INTRODUCTION
Subconjunctival hemorrhage is a benign and self-limiting
condition that often occurs without any obvious trauma
to the eye. Most cases do not cause pain or changes in
vision, and thus no active management is required. We
present a case of subconjunctival hemorrhage that
resulted in the formation of bullae and caused significant
ophthalmic morbidity in a patient on therapeutic anticoagulation with adenoviral conjunctivitis.

CASE
A 78-year-old female with a past medical history of optic
neuropathy and atrial fibrillation on warfarin presented
with two weeks of progressive bilateral eye redness,
swelling, pain, and blurry vision. Initially, the patient was
experiencing symptoms only in her right eye, and the
contralateral eye became involved throughout the course
of her illness. Examination was remarkable for bilateral
bullous subconjunctival hemorrhage and trace edema of
her eyelids with tenderness to palpation (Figure 1).
Tonometry, computed tomography scan of the orbits,
and fluorescein stain were all unrevealing. A viral
respiratory pathogen panel was positive for adenovirus,
and INR appropriately elevated to 2.13 on admission.
Other laboratory tests were within normal limits. She was
treated with carboxymethylcellulose sodium 0.5%
ophthalmic solution and erythromycin 0.5% ophthalmic
ointment 5mg/g three times daily, which significantly
improved both her pain and blurry vision. The patient was
discharged and scheduled to follow up with oculoplastics
and ophthalmology.

Figure 1. Bilateral subconjunctival hemorrhage with edematous eyelids
and watery discharge.

DISCUSSION
The conjunctiva is a thin transparent membrane that
covers the sclera as well as the inner surface of the
eyelid.1 Inflammation of this membrane is known as
conjunctivitis.1 Viral conjunctivitis is typically caused by
adenovirus and is the most common overall cause of
infectious conjunctivitis.2 The virus itself is spread through
direct contact with an infected individual or their
secretions as well as contaminated objects or surfaces.3
Most often, patients will present with injection, watery or
mucoserous discharge, and a burning or gritty sensation
affecting one of their eyes.4 However, it is common for
the other eye to become involved within the first 24-48
hours.4 This condition is self-limiting, with symptoms
worsening over the first three to five days, followed by a
gradual recovery over two to three weeks.4 While antiviral
agents are not indicated in the treatment of viral conjunctivitis, patients may benefit from the use of topical antihistamines, decongestants, or lubrication by either antibiotic
or nonantibiotic ointments.1 The patient in this case did
not demonstrate the classic presentation of viral conjunctivitis, specifically with regard to her prolonged period of
worsening symptoms, and bullous subconjunctival
hemorrhage. Subconjunctival hemorrhage is a common
condition and refers to bleeding into the compartment
located between the conjunctiva and the episclera.5
There are many know risk factors associated with subconjunctival hemorrhage, including acute conjunctivitis,
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trauma, contact lens use, systemic vascular disease, and
anticoagulation therapy.5,6 Alternatively, bullous subconjunctival hemorrhage, marked by the presence of
conjunctival bullae, is an exceedingly rare condition that
is generally limited to cases of ocular trauma with scleral
rupture. 5 To date, there appears to be no cases of
non-traumatic bullous subconjunctival hemorrhage, such
as that seen in our patient. Without other known risk
factors, it is possible that her warfarin use, in the setting
of adenoviral conjunctivitis, contributed to this unique
presentation.
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PULMONARY MEDICINE

Case Report of E-cigarette Associated Lung Injury
in a Healthy Female
Mario Fonseca-Paricio, MD, Alan Gandler, MD, Boyd Hehn, MD

CASE DESCRIPTION
This is a case of a woman presenting with four days of
diarrhea and dyspnea found to have E-cigarette or vapingassociated lung injury (EVALI).
The patient is a 30-year-old woman who presented to the
hospital with a chief complaint of dyspnea on exertion.
She developed dyspnea seven days prior to presentation;
it was minimal at rest, however symptoms worsened with
exertion. Her symptoms included fevers, intermittent
chills, night sweats, dry persistent cough, and four days of
profuse, watery diarrhea. She did not have sinus pain or
congestion, headaches, or sore throat. Due to bloody
diarrhea she sought medical care.
The patient had no allergies and took no medications
regularly. She had a history of exercised-induced asthma
during childhood that had resolved. Surgical history was
notable for seven surgeries for bilateral breast
fibroadenomas. Family history was notable for
BRCA-negative breast cancer in her mother.
She works as a real estate agent, with no known specific
exposures. Ten days prior to admission, she had spent
time with her nephew who she reported as having several
symptoms consistent with an upper respiratory infection.
She does not smoke cigarettes. She had been using
electronic cigarettes with marijuana for 6 months earlier
in the year, however due to news reports, she had recently
stopped. She would smoke marijuana from electronic
cigarettes four days a week with cartridges lasting about
one week. Patient used no other drugs or alcohol. No
history of homelessness or incarceration. Patient is
sexually active with one male partner with no prior HIV or
sexually transmitted infections (STI). On review of systems,
patient noted to have an unintentional 5-pound weight
loss over the past one week.
On initial vital signs, she had temperature of 38.2 C, HR of
117 bpm, blood pressure of 108/74 mmHg, respiratory
rate of 22 breaths/minute, 86% on ambient air and 95%
on 2 liters nasal cannula of oxygen. She was admitted to
the medical service due to a new oxygen requirement.
Physical exam was notable for of a well-developed and
nourished adult female in no acute distress on nasal
cannula able to speak in full sentences. Pulmonary exam
showed scattered rales with no wheezing. She had
tachycardia with no jugular venous distention. She had no
abdominal pain or lower extremity swelling.

Figure 1. High-resolution CT of the chest demonstrating diffuse ground-glass
opacities with septal thickening. There is a peripheral predilection with
subpleural sparring disease.

Laboratory results on presentation revealed a leukocytosis
of 28,000 cells/mm3 with 92% neutrophils and a platelet
count of 558 cells/mm3. Electrolytes revealed a
potassium of 2.9 mEq/L, HCO3 of 22 mEq/L. Liver
function tests showed an AST/ALT of 119/73 IU/L. Lipase
was normal. Lactate normal at 1.2 mmol/L. Procalcitonin
was 0.64 ng/mL (normal < 0.08 ng/mL).
Respiratory pathogen panel nasopharynx swab detected
human rhinovirus/enterovirus on PCR. Blood cultures
showed no growth. Influenza A/B, RSV PCR nasal swab
was negative. Clostridium difficile toxin DNA, and gastrointestinal stool infectious panel were negative. HIV
antibody and antigen combination were non-reactive.
Streptococcus pneumoniae and Legionella antigen urine
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Figure 2. On the left, Romanowski stain showing numerous alveolar macrophages with abundant vacuolated cytoplasm. On the right, positive orangestained droplets within the cytoplasmic vacuoles of alveolar macrophages.

test were negative. Urine pregnancy test was negative.
Urine drug screen was positive for cannabinoid.
Chest x-ray on initial evaluation revealed diffuse patchy
bilateral opacities with no effusions. Right upper quadrant
ultrasound was normal.
Patient was admitted and placed on azithromycin and
ceftriaxone for community-acquired pneumonia.
Subsequently was changed to levofloxacin 750 mg oral.
Due to continued oxygen desaturation on ambient air,
intermittent fevers, and tachycardia for two-day duration
despite antibiotics and supportive care a high-resolution
computed topography (HRCT) of the chest was obtained.
HRCT demonstrated widespread ground glass opacities
and scattered septal thickening bilaterally without lobar
predominance, with diffuse subpleural sparing (Figure 1).
There were dense consolidations seen in the bilateral lobes
and the right middle lobe. These findings were consistent
with inhalation-induced lung injury as well as viral and
atypical pneumoniae.
Patient subsequently underwent bronchoscopy. Findings
notable for normal airway with parenchymal infiltrates.
Bronchoalveolar lavage (BAL) with a transbronchial biopsy
were performed. Right middle and left upper lobe BAL
pathology revealed oil-red O stain showing intracytoplasmic lipid droplets in alveolar macrophages consistent
with lipid laden-macrophages (Figure 2). Transbronchial
biopsy of the left lingula showed pneumonitis; there was
interstitial edema, inflammation, mild fibrosis, hyperplasia
of type II pneumocytes, organizing pneumonia, and
macrophages in the airspace.
The history, imaging and pathology were felt to be
consistent with EVALI. Due to this the patient was placed
on three days of methylprednisone 250 mg every 12
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hours. Upon the second day of this regimen, she no
longer had ambulatory desaturation with stable vital signs.
She finished a seven-day course of antibiotics while
hospitalized. She was discharged on 40 mg daily of
prednisone for with subsequent pulmonary medicine
outpatient visit, which has not yet occurred.

DISCUSSION
EVALI is lung injury due to the inhalation of non-combustible
aerosol containing “nicotine, flavors, propylene glycol, and
vegetable glycerin”, which includes battery operated
devices that include electronic cigarettes (e-cigarettes).1
EVALI is becoming a more prevalent, being formally
recognized in 2019, with over 2,000 cases reported in the
United States by the Center for Disease Control (CDC).2,3
This new clinical entity has led to interest in the
pathogenesis of EVALI. Though no single agent has been
implicated in the pathogenesis of EVALI, many patients
have used nicotine, tetrahydrocannabinol (THC), and
cannabinoid (CBD) oils.2,4 Another agent of interest
implicated in in the pathogenesis of EVALI is vitamin E
acetate, which has been associated with impairment of
pulmonary surfactant.5,6
EVALI is a type of acute lung-injury presenting with a
wide-range of pulmonary complaints and findings. The
most common presenting symptoms fevers, tachycardiac,
and tachypnea.4 One review revealed gastrointestinal
symptoms in about 80% of patients. In this same review,
67% of patients presented with hypoxemia, and about 30%
of patients had oxygen saturation less than 88%.4 Chest
imaging generally reveals marked bilateral opacities. The
typical chest CT finding is ground glass opacities marked
by subpleural sparing.4,7 These findings, however, can be
seen in other pathological process and thus may warrant

further investigations with bronchoscopy and BAL. EVALI
leads to alveolar damage and fibrinous pneumonitis and
has a wide range of histopathological findings. Most
reported cases involve variation in cell counts from BAL,
though usually with a predominance of neutrophils.4 Many
cases report Oil-red-O staining lipid-laden macrophages
as in this patient.8
One confounding variable in this case was a positive
rhinovirus/enterovirus test, which could explain some of
her symptoms. However, it is unlikely that this viral infection
would have produced such significant clinical decompensation in an otherwise young and healthy patient. Moreover,
clinical history, ground glass opacities with subpleural
sparing, and lipid-laden macrophages with pneumonitis
are consistent with our current understanding of EVALI.

CONCLUSION
In patients who present with respiratory complaints and
history of E-cigarettes, EVALI should be strongly
considered. This is particularly true in those with
hypoxemia and respiratory distress. A chest CT is an
Important diagnostic modality to help identify and
inhalation pattern injury, but many patients may need
further testing with bronchoscopy and BAL. We presented
a case of a young, healthy patient who had significant
respiratory distress secondary to EVALI.
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LITERATURE REVIEW

Serum Ammonia and Folate Levels:
Opportunities for High Value Care
R. Benson Jones Jr. MD, Sean Dikdan MD, and Bracken Babula, MD

High value care encompasses a variety of principles
including ordering tests with high diagnostic yield, while
reducing low value practices. Two tests that are
frequently ordered but rarely contribute meaningfully to
the diagnosis and management of patients are serum
ammonia levels and serum folate levels. The American
Association for the Study of Liver Disease (AASLD)
recommends against using blood ammonia levels for
hepatic encephalopathy (HE), stating that the test does
not add “any diagnostic, staging, or prognostic value”
for patients with chronic liver disease1. The American
Society for Clinical Pathology (ASCP) in the Choosing
Wisely campaign by the American Board of Internal
Medicine recommended considering “folate supplementation instead of serum folate testing in patients
with macrocytic anemia2.” In the following discussion,
we will discuss the evidence behind these claims in
addition to our own argument against routinely ordering
serum ammonia and serum folate levels in the
assessment of hepatic encephalopathy and anemia,
respectively. We will also provide a preliminary analysis
of the cost related to these tests and the potential
impact of changing ordering practices at our institution,
a large urban academic medical system.

Serum Ammonia Levels in the Assessment
of Hepatic Encephalopathy
HE is a brain dysfunction caused by liver pathology,
portosystemic shunting, or both. It manifests in a wide
spectrum of neurological and psychiatric abnormalities
and is typically a clinical diagnosis using the West Haven
Criteria (WHC) classification system1. Because 85% of
ammonia is detoxified by the liver and excreted as urea
in urine (with muscle and brain tissue metabolizing the
rest), it has been theorized that hyperammonemia
contributes to HE 3 . Astrocytes synthesize more
glutamine in the setting of increased ammonia,
precipitating reactive oxygen species, astrocyte
swelling, and enhanced gamma-aminobutryic acid
(GABA) inhibition, manifesting as cerebral dysfunction.
In addition, bleeding, infection, and renal failure all
precipitate HE and incidentally promote hyperammonemia. With these underlying factors in mind, it
would appear that ammonia levels would be helpful in
the diagnosis of HE. Multiple issues with serum
ammonia, however, limit its usefulness. Fist clenching,
the use of a tourniquet during the process of
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phlebotomy and processing time can lead to false
elevations or spurious results 4-6. The sensitivity and
specificity of a venous ammonia greater than 55
µmol/L) to diagnose HE were 47.2% and 78.4%,
respectively. In one study, 60% of the patients with
grade 3 HE by the West Haven Criteria had a normal
serum ammonia level 7. These test characteristics
underlie the AASLD recommendation to avoid checking
serum ammonia in patients with chronic liver disease
to diagnose or assess the severity of HE. Covert HE (i.e.
Grade I HE by WHC) remains a diagnostic challenge
given the lack of reproducibility of clinical findings, but
trivial lack of awareness, shortened attention span, and
altered sleep rhythm can raise suspicion for this
diagnosis in patients with liver disease.

Institutional ordering characteristics and associated
healthcare charges for serum ammonia
Between the initial date of data recording (11/25/2016) to
the day the database was accessed (1/14/2020), there
were a total of 7541 serum ammonia orders. Of these
orders, 6206 orders occurred in the inpatient setting,
with a charge of $201 per order according to the publicly
available institutional chargemaster8 (Figure 1). Note that
these charges do not reflect what the patient pays;
insurance companies dictate how much reimbursement
the institution receives. The average dollar amount of
charges per month attributable to inpatient serum
ammonia orders alone is $31,984.76, calculated by
dividing the total charge amount for all serum ammonia
orders over the examined time ($1,247,406) by the
number of months of data (39 months). The departments
who ordered the most serum ammonia levels are
Medicine (2404 orders total), Emergency Medicine in the
flagship hospital (1702), and Emergency Medicine in a
nearby community hospital (702) (Figure 2).

Serum Folate Levels in the Assessment
of Anemia
Folic acid (folate) is a critical water-soluble B vitamin
used in the process of DNA synthesis. Deficiency of
folate manifests in newborns as neural tube defects
and classically as macrocytic, megaloblastic anemia in
adults. In an effort to reduce the incidence of neural
tube defects, the US government began mandating
supplementation of every 1 gram of grain with 140 mcg
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the assay itself: 400 mcg folate tablets range from $0.03
per tablet to $0.20 cents per tablet, while the charge for
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programs from commercial laboratory corporations to
$207 by the institutional chargemaster8, 12 (Serum folate
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of folic acid in 1996, leading to a 36% reduction in the
prevalence of neural tube defects in the US.9 This
fortification has led to a significant decline in prevalence
of adult folate deficiency. In an analysis of the National
Health and Nutrition Examination Survey (NHANES)
study group, Pfeiffer and colleagues found that “the
percentage of the population with low serum folate (<3
ng/mL) declined from 21% in the period before
fortification (1988--1994) to <1% of the total population
in the period immediately following fortification 10
(1999--2000)." Despite low prevalence of folate
deficiency clinicians continue to order the assay, which

Serum ammonia and serum folate levels should not be
routinely ordered in the diagnosis and management of
hepatic encephalopathy or in the diagnosis of anemia,
respectively. Chargemaster charges and simple numerical
counts of orders shows a significant charge burden for
tests that do not significantly impact patient care. While
this analysis does not provide cost estimates to the
institution as a whole as it does not incorporate assay
costs and lab personnel processing time, it reveals the
charges that minimal utility tests impose on the healthcare
system. One proposal to reduce ordering folate levels is
to replace the combined folate/B12 order with individual
folate and B12 orders in physician preference lists. Future
work will assess the impact of iterative changes on the
reduction of these orders and strive to understand the
cost of these assays to the institution.
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EDITORIAL

Refusing to be Labeled
Jennifer Perugini
The tension in the room was palpable as ankles bounced
feet and charged glances were shared from across
tables. About 15 of my medical school peers were
listening to a lecture on plastic surgery and
reconstruction techniques, however ‘listening’ may be
a generous term for what we were doing. There was
only one thing running through every brain in that
room: will it be high enough? We were anxiously
awaiting our USMLE Step 1 scores. I looked around the
room and, like me, almost everyone had their cell
phone resting in their lap, trying not to make it too
obvious that a webpage was being refreshed every few
seconds. One by one my classmates took turns slipping
outside to watch a number pop up on a small screen
– a number we had been programmed to associate
with our future success, or lack thereof. Had we chosen
enough correct answers on that fateful exam to be
destined for greatness or were we doomed to an
insignificant career in a land far, far away?
The USMLE Step 1 exam had been so hyped up in my
first two years of medical school that I almost couldn’t
remember a time when the results of the exam weren’t
at the forefront of my mind. The test was brought up
during my interview day, during the second-look event
I had attended, in our first welcome address upon
arriving on campus, and in every course henceforth.
The importance of the assessment, by the time I
reached the end of my second year, had been so
ingrained that when my family asked what I was studying
for I almost gaped with incredulousness. “You mean
you don’t know what Step 1 is?”, I proclaimed, eyebrows
shooting upward. “This is the exam that will determine
the rest of my life – it will dictate what type of doctor I
can be and where I can train!” Despite my best efforts,
I couldn’t quite seem to get my point across. My parents,
having no exposure whatsoever to the drawn-out
process of becoming a doctor, couldn’t understand the
monumental gravity of this single exam, this one
number on a tiny cell phone screen. They were taken
aback that one score could dictate so much – and
honestly, I couldn’t quite justify it myself.
My own journey into the field of medicine began from
a very young age. I did not come from a family of
physicians or overcome a serious childhood illness
leading to a sacrosanct devotion to the field. I was,
however, taken on an annual hospital pilgrimage on my
birthday to stare, on tiptoes, at the newborns who
would forever share my same date and location of
birth. Each one was carefully swaddled in that iconic
white receiving blanket with blue and pink stripes that,

despite the ever-changing medical field, has remained
a familiar constant—the global signifier of hospital birth.
I understood that I might never meet these tiny humans
or even ever know their names, yet somehow, I still felt
a strong sense of connection. Though new HIPAA laws
eventually curtailed my yearly visits to the hospital
nursery, I had already been jump-started on my medical
journey. Whether it was candy-striping in high school,
interning in an Italian eye clinic in college, or distributing
mosquito nets in remote villages of Laos after
graduation, my passion for clinical care never wavered.
It is with this same sustained dedication that I have
navigated medical school, and it is how I will approach
each day as an intern and resident physician.
I didn’t score highly on Step 1 of the USMLE. Writing
these words or even worse – being forced to say them
out loud – pings the edges of my heart the way muscle
jumps backwards from the sting of cautery. From the
very first moment I saw those three digits, I have felt
branded with a mark of incompetence. I have envisioned
a bubble above my head that stays with me wherever I
go, obstinately displaying my worth for the world to
see. I have been turned down from elective rotations,
passively dismissed from residency interviews, and even
told by one mentor that I am “not cut out for a surgical
subspecialty based on [my] Step 1 score.”
It has taken me a lot of time, and a lot of reflection, to
come to terms with the fact that my future, let alone
my self-worth, will not be determined by one exam I
took during medical school. I have honored almost all
of my clinical rotations, have received heartfelt letters
from patients sharing gratitude for being the only
person to truly listen to them, have sought out medical
opportunities on four continents in two languages, and
have volunteered with some of the most vulnerable
populations in society. Numeric scores aside, I refuse to
believe that I will be anything less than the skilled,
hardworking, and compassionate Obstetrician
Gynecologist that I can envision so clearly.
As a medical community, by marginalizing students
who perform below average on USMLE testing, we
stifle passion and creativity. By telling students that they
are not qualified for a certain specialty based on a test
score, we smother confidence and stifle spirits. And
when it comes to the best interest of our patients, are
we not doing them a disservice by attempting to filter
out people with lower scores, despite the energy and
passion those students may bring to the field? I hope to
be the kind of intern, resident, and future attending
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OB-GYN that encourages students, regardless of USMLE
scores, to pursue the specialty that most speaks to
them, the patient population they feel most empathy
for, and the disease processes that make them feel
intellectually vitalized. I felt all of these things, and more,
when I discovered my passion for OB-GYN. For a
medical student, discovering one’s specialty of choice
sparks a feeling comparable to coming home after a
long, long time away. And who are we, as medical
professionals, to quell such a feeling?
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Much to Jennifer’s contentment, the score reporting
policy for Step 1 of the USMLE was changed from
three-digit reporting to pass/fail reporting shortly after
she wrote this piece. This policy change is to be
implemented in January 2022 .

Agnes Tsuda
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